Geron Hires Stifel to Sell Stem Cell Assets, CEO Says

Geron Corp. hired Stifel Nicolaus & Co. to sell its embryonic stem cell therapy, the first approved in the U.S., as the company changes its focus to cancer drugs, Chief Executive Officer John Scarlett said.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.